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Lumazine Synthase Protein 
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for high-field MRI
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With the applications of magnetic resonance imaging (MRI) at higher magnetic fields increasing, 
there is demand for MRI contrast agents with improved relaxivity at higher magnetic fields. 
Macromolecule-based contrast agents, such as protein-based ones, are known to yield significantly 
higher r1 relaxivity at low fields, but tend to lose this merit when used as T1 contrast agents (r1/
r2 = 0.5 ~ 1), with their r1 decreasing and r2 increasing as magnetic field strength increases. Here, we 
developed and characterized an in vivo applicable magnetic resonance (MR) positive contrast agent 
by conjugating Gd(III)-chelating agent complexes to lumazine synthase isolated from Aquifex aeolicus 
(AaLS). The r1 relaxivity of Gd(III)-DOTA-AaLS-R108C was 16.49 mM−1s−1 and its r1/r2 ratio was 0.52 
at the magnetic field strength of 7 T. The results of 3D MR angiography demonstrated the feasibility 
of vasculature imaging within 2 h of intravenous injection of the agent and a significant reduction in 
T1 values were observed in the tumor region 7 h post-injection in the SCC-7 flank tumor model. Our 
findings suggest that Gd(III)-DOTA-AaLS-R108C could serve as a potential theranostic nanoplatform 
at high magnetic field strength.
With the applications of MRI in higher magnetic fields (> 7 T) both in preclinical and clinical settings 
increasing, there are needs to develop MRI contrast agents with improved relaxivity at higher magnetic 
fields. From MRI perspective, the advantage of higher magnetic field is attractive, as it is expected to 
drastically increase signal to noise ratio (SNR) and resolution1,2. However, it is generally observed that 
spin-lattice time (T1) increases and converges for different tissues as the magnetic field strength increases, 
which reduces contrast for T1-weighted exams using the same imaging parameters used at conventional 
1.5 or 3 T3,4. As contrast to noise ratio (CNR) is critical for the sensitivity and specificity of MRI exams, 
this reduction of inherent T1 contrast necessitates the development of efficient in vivo compatible positive 
contrast agent with good relaxivity characteristics at higher magnetic field5–8.
Protein cage nanoparticles, including ferritins, encapsulins, and virus-like particles (VLPs), have been 
widely used as nanoscale delivery vehicles for diagnostic and/or therapeutic reagents9–21 as they not 
only have well-defined structure and size, but also consist of biocompatible and biodegradable bioma-
terials, polypeptides22. The highly symmetrical and uniformly composed architecture of protein cage 
nanoparticles allow them to be manipulated in a highly controlled manner, resulting in the production of 
reproducible nanoscale multifunctional particles9–21. VLPs have been extensively studied as supramolec-
ular templates for the conjugation of small molecule contrast agents, such as the chelated paramagnetic 
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gadolinium ion (Gd(III)), which is frequently used as a positive contrast agent for magnetic resonance 
imaging (MRI)23–27.
Macromolecule (such as protein)-based contrast agents are known to yield significantly higher r1 
relaxivity due to decreased local motion and increased correlation time28–30; however in vivo applicable 
positive contrast agents, which maintain considerably enhanced r1 relaxivity (> 10 mM−1s−1) with an 
acceptable r1/r2 ratio (0.5 ~ 1) at high magnetic field (7 T), are a rarity8,31–34.
In the present study, we used lumazine synthase, isolated from the hyperthermophile Aquifex aeolicus 
(AaLS), as a nanoscaled template for T1 contrast conjugates as illustrated in Fig.  1A and evaluated its 
potential as an in vivo MR contrast agent at the magnetic field strength of 7 T. AaLS is composed of 60 
identical subunits that form an icosahedral capsid architecture (T = 1 state) with respective exterior and 
interior diameters of 15.4 nm and 9 nm35. AaLS is known to catalyze the penultimate step of riboflavin 
biosynthesis within cells36. The structural robustness and functional plasticity of AaLS make it an attrac-
tive candidate for a versatile bio- and nanotechnological platform37–44. Its hollow spherical architectures 
have been used as templates for the encapsulation of functional proteins37,43–46 and the biomimetic syn-
thesis of iron oxides44, as well as delivery vehicles of therapeutic and/or diagnostic reagents32,34. AaLS 
has also been engineered into multifunctional building blocks for fabricating uniform layer-by-layer 
(LbL) assemblies using non-covalent interactions between surface-displayed hexahistidine and Ni-NTA 
of AaLS39. For our application, Gd(III)-chelating agent complexes were attached at position 108 with 
cysteine (R108C), which is known to be exposed on the exterior surface of AaLS.
Experimentally, Gd(III)-DOTA-AaLS were characterized by mass spectroscopy (MS) to ensure that 
AaLS was modified with only one Gd(III)-DOTA complex per subunit. Transmission emission micros-
copy (TEM) was used subsequently to ensure that the cage architecture and stoichiometry of AaLS is 
not significantly altered in the Gd complex conjugation. Next, r1 and r2 MR relaxivities were measured at 
1.4 T and 7 T with multiple Gd concentration phantoms. In vivo imaging experiments were performed 
at the magnetic field strength of 7 T using a tumor bearing mouse, before and after the injection of 
Gd(III)-DOTA-AaLS-R108C. Observed signal behaviors were directly compared with the correspond-
ing results from the injection of conventional Gd-DOTA (DOTAREM) for both vasculature and tumor 
regions.
Figure 1. (A) Surface and ribbon diagram representations of AaLS-RC (PDB: 1HQK) and site-specific 
conjugations of Gd(III)-DOTA (red dots) to the exterior surface of AaLS-R108C. (B) Molecular mass 
measurements of dissociated subunits of untreated AaLS-R108C (bottom) and Gd(III)-DOTA-AaLS-R108C 
(top). Calculated and observed molecular masses are indicated. (C) Size exclusion profiles of untreated 
AaLS-R108C (bottom) and Gd(III)-DOTA-AaLS-R108C (top). (D) Transmission electron microscopic image 
of negatively stained untreated AaLS-R108C (right) and Gd(III)-DOTA-AaLS-R108C (left) with 2% uranyl 
acetate.
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Materials and Methods
Gd(III)-DOTA-AaLS-R108C as MRI contrast agent (MRI CA). AaLS does not have sufficiently 
large inter-subunit spaces for Gd(III)-chelating agent complexes to freely diffuse into its interior cavity. 
Thus, to attach Gd(III)-chelating agent complexes in a site-specific and number controlled manner, we 
substituted the arginine residue at position 108 with cysteine (R108C), which is known to be exposed on 
the exterior surface of AaLS and readily to be used as a site for the attachment of small molecules47–49. 
To fully saturate the chelating agents (maleimido-monoamide-DOTA (DOTA-mal)) with Gd(III), they 
were incubated with an excess of Gd(III) prior to conjugation to AaLS. Subsequently, AaLS was treated 
with 3 mol equivalents of Gd(III)-DOTA-mal for attachment at room temperature with vigorous shaking 
overnight (Fig.  1A). Unreacted Gd(III)-DOTA-mal were removed by extensive dialysis with multiple 
changes of buffer. The extent of the conjugation was determined by subunit mass measurements using 
electrospray ionization time-of-flight mass spectrometry (ESI-TOF; Xevo G2 TOF).
Cell and animal models. Squamous cell carcinoma (SCC)-7 cells were cultured in RPMI1640 medium 
containing 10% (v/v) fetal bovine serum and 1% (w/v) penicillin-streptomycin at 37 °C under conditions 
of 5% CO2. To generate a tumor-bearing mice model, SCC-7 (1 × 106) cells in phosphate-buffered saline 
(PBS) were injected subcutaneously into the right flank of six-week-old female BALB/c nude mice weigh-
ing 20–25 g (Harlan Laboratories). When the tumor volume reached approximately 100 mm3, the mice 
were used for in vivo MR imaging. All animal studies were performed in compliance with the guidelines 
of the local ethics committee for animal care and use, and were approved by the Institutional Animal 
Care and Use Committee of Ulsan National Institute of Science and Technology.
Relaxivity Measurements. We measured the T1 and T2 relaxation times of the Gd(III)-DOTA-AaLS 
under 1.4 T (Bruker Minispec MQ60 TD-NMR, 60 MHz) and 7 T (Bruker BioSpec 70/16 US, 300 MHz) 
magnets. At 60 MHz, the T1 relaxation times of the Gd(III)-DOTA-AaLS were measured using the inver-
sion recovery (IR) method with the IR delay ranging from 0–20000 ms. T2 relaxation times were meas-
ured with a CPMG sequence with echo spacing (TE) of 1 ms and recycling time (TR) of 1.5 s. At 300 MHz, 
the T1 relaxation time was estimated using a sequence of rapid acquisition with relaxation enhancement 
(RARE) at variable repetition times; 10 TR values of 20–5000 ms were used with echo time (TE) of 
7.6 ms. The T2 relaxation time was measured using a multi-slice multi-echo (MSME) method at TR of 
5000 ms with 50 TE values in the range of 20–1000 ms. The proton relaxivities (r1 : longitudinal relaxivity 
and r2 : transverse relaxivity) were determined by measuring the T1 relaxation times and T2 relaxation 
times of six different Gd concentrations of Gd(III)-DOTA-AaLS-R108C (0.074, 0.037, 0.0185, 0.00925, 
0.004625, and 0 mM). Both relaxivities r1 and r2 were calculated from the slope of the relaxation rate R1 
(1/T1) and R2 (1/T2) as a function of concentration (mM) of contrast agent, respectively. We previously 
demonstrated that the relaxivities of protein cage nanoparticles conjugated with Gd(III)-chelating agent 
can be determined by measuring the T1 relaxation time and corresponding Gd(III) concentrations23. The 
relaxivities of Gd(III)-DOTA-AaLS-R108C were calculated using the linear relaxivity equation used in 
a previous study23,26. The proton relaxivities of saline solutions with untreated AaLS-R108C at identical 
concentrations were determined, as AaLS may also give T1 enhancement as well.
In vivo imaging of tumor-bearing mice. All tumor-bearing mice weighing 20–25 g (tumor vol-
ume: ~100 mm3) were scanned using 7 T MRI (Bruker Biospec) with a transceiver RF volume coil 
(diameter: 40 mm) for the mouse body, maintained under anesthesia with 1.0–1.5% isoflurane. 
Radiofrequency power and receiver adjustments were continuously maintained for each scan. Four mice 
were examined to investigate the vasculature imaging capabilities and the tumor accumulation efficacy 
of Gd(III)-DOTA-AaLS-R108C at high field (7 T) and two mice in the control group were assessed 
using Gd-DOTA (DOTAREM) as a reference. Four mice were injected intravenously with 350 μ l of 
Gd(III)-DOTA-AaLS-R108C (concentration: 17.143 mM) as a bolus into the tail vein. Also in the same 
manner, two mice were injected intravenously with 350 μ l of DOTAREM (concentration: 17.857 mM) as 
a bolus into the tail vein for the direct comparisons.
For the longitudinal and direct comparison of the vasculature imaging capability and delivery efficacy 
of Gd(III)-DOTA-AaLS-R108C to the tumor region, three dimensional (3D) MR angiography (MRA) 
and T1-mapping were adopted at six time points (1, 2, 3, 7, 12, and 30 h) after the intravenous injec-
tion of the contrast agent at a dose of 0.3 mmol/kg. To this end, a 3D-Fast Low-Angle Shot (FLASH) 
and a RARE with variable repetition time TR (RAREVTR) sequence were used for a high-resolution 
angiogram and T1-map, respectively. MR parameters were set as follows: TR = 13 ms, TE = 2.1 ms, flip 
angle = 20°, FOV = 30 × 30 × 30 mm3, matrix size = 256 × 256 × 256 for 3D-FLASH; TR = 8 values in the 
range of 280–5000 ms, TE = 6.0 ms, field of view (FOV) = 30 × 30 mm2, slice thickness = 1 mm, matrix 
size = 128 × 128 for RAREVTR T1 measurements. MRA were reconstructed using maximum intensity 
projection (MIP) protocol with Bruker Paravision software (PV6) and T1-maps were generated by a 
mono-exponential fitting method (Matlab, R2013a, The MathWorks Inc., USA).
Results
Characterization of Gd(III)-DOTA-AaLS-R108C. The extent of the Gd(III)-DOTA-conjugation was 
determined by ESI-TOF MS, following the dissociation of Gd(III)-DOTA-mal treated AaLS-R108C. The 
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subunit molecular masses of AaLS-R108C and Gd(III)-DOTA-mal treated AaLS-R108C were determined 
to be 27415.0 and 28095.0 Da, respectively, which are in an excellent agreement with the corresponding 
calculated values of 27413.6 and 28096.9 Da and only one mass peak was observed (Fig. 1B). Mass spec-
trometric data indicated that all subunits of AaLS-R108C were modified with only one Gd(III)-DOTA 
complex (60 Gd(III)-DOTA per cage). The Gd-content of Gd(III)− DOTA conjugated AaLS-R108C 
was independently measured with inductively coupled plasma-mass spectrometry (ICP-MS) and the 
Gd-content was determined to be 0.86 Gd(III) per subunit, which is slightly lower than the value deter-
mined by MS probably due to slight sample loss during ICP-MS sample preparation23. To avoid over-
estimation of the relaxivity of Gd(III)-DOTA–conjugated AaLS-R108C (Gd(III)-DOTA-AaLS-R108C), 
we used the Gd content as determined by MS23. Gd(III)-DOTA-AaLS-R108C was eluted at the same 
position as untreated AaLS-R108C in size exclusion chromatography (Fig. 1C) and transmission electron 
microscopic images of negatively stained Gd(III)-DOTA-AaLS-R108C showed its intact cage architec-
ture with the same size as untreated AaLS (~15 nm in diameter, Fig. 1D). Zeta potential measurements 
revealed that Gd(III)-DOTA-AaLS-R108C had slightly lower negative surface charge (− 8.2 mV) than 
that of AaLS-R108C (− 5.5 mV) probably due to the introduced Gd(III)-DOTA. These results demon-
strate that Gd(III)-DOTA-mal conjugation to AaLS-R108C does not significantly alter its cage architec-
ture or stoichiometry.
Relaxivity measurements with phantoms. The T1 relaxation times became shorter under 
both 1.4 T and 7 T, as the Gd(III) concentrations increased (Fig.  2A-1,C-1) suggesting that the 
Gd(III)-DOTA-AaLS-R108C supramolecular template accelerated the recovery of net magnetization. 
Corresponding T2 relaxation times also decreased as Gd(III) concentrations increased (Fig.  2A-2,C-
2). Gd(III)-DOTA-AaLS-R108C showed higher T1 relaxivity (r1 = 30.24 mM−1s−1, r2 = 41.42 mM−1s−1, 
Fig.  2A-3) per Gd(III) under 1.4 T (37 °C) than did free Gd(III)-chelating agents (4–5 mM−1s−1). 
Although the T1 relaxivity of Gd(III)-DOTA-AaLS-R108C decreased (r1 = 16.49 mM−1s−1, 
r2 = 31.86 mM−1s−1, Fig.  2C-3) under high magnetic field (7 T, room temp.), the measured r1/r2 val-
ues of Gd(III)-DOTA-AaLS-R108C were 0.73 and 0.52 for 1.4 T and 7 T, respectively, indicating that 
Gd(III)-DOTA-AaLS-R108C remains as the optimal T1 contrast agent at 7 T23,26. The T1 and T2 relaxation 
times measurements with increasing concentration of untreated AaLS-R108C at identical experimental 
conditions were shown in Fig. 2B-1,B-2 for 1.4 T. Corresponding relaxations times measurements were 
shown in Fig. 2D-1,D-2 for 7 T. The relaxivities of untreated AaLS-R108C at 1.4 T (r1 = 0.37 mM−1s−1, 
r2 = 1.29 mM−1s−1, Fig.  2B-3) and 7 T (r1 = 1.02 mM−1s−1, r2 = 3.14 mM−1s−1, Fig.  2D-3) were deter-
mined as reference.
To evaluate the potential usage of Gd(III)-DOTA-AaLS-R108C as an in vivo T1 contrast agent at high 
magnetic field, we captured T1-weighted MR images of the phantom using a volume coil with a 7 T 
MRI scanner using a RAREVTR sequence at 4 TR values (100, 500, 1000, and 2000 ms). T1-weighted 
in vitro phantom images of PBS control (S1A), AaLS-R108C only (S1B) and Gd(III)-DOTA-AaLS-R108C 
with increasing concentrations (S1C) were shown in supporting Fig. 1. While the MR signal intensities 
of Gd(III)-DOTA-AaLS-R108C were significantly enhanced at short TRs (500 and 1000 ms), those of 
the PBS control and AaLS-R108C were not, as shown in supporting Figure S1C, S1A, and S1B, respec-
tively. As the Gd concentration of Gd(III)-DOTA-AaLS-R108C is increased, the accelerated R1 values of 
Gd(III)-DOTA-AaLS-R108C led to contrast enhancement resulting in brighter images at short TRs as 
shown in Figure S1C. For the comparisons with conventional DOTAREM, saturation recovery signals 
with RAREVTR at multiple TR values were plotted together, where the Gd concentrations (0.0185, 0.037, 
and 0.074 mM) were kept same for both Gd(III)-DOTA-AaLS-R108C and DOTAREM as shown in S1D. 
Increased R1 values were apparent for Gd(III)-DOTA-AaLS-R108C at the same concentration, which led 
to enhanced r1 relaxivity over conventional DOTAREM at 7 T.
In vivo characterizations. 3D MR angiograms and T1 maps of tumor-bearing mice were generated 
to evaluate both the feasibility of MR angiography and the tumor accumulation efficacy using newly 
developed Gd(III)-DOTA-AaLS-R108C. Identical experiments and analysis were repeated with conven-
tional DOTAREM for direct comparisons. From these MR data, region of interest (ROI) analysis was also 
employed to measure regionally averaged T1 values and corresponding signal enhancement.
The decreasing trend in T1 values of the tumor region of mice was consistently observed after the time 
point of ~7 h post-Gd(III)-DOTA-AaLS-R108C injection. Figure S2A and S2B illustrates this, showing 
T1 maps before and 30 h after the injection. Supplementary Figure S2C shows the corresponding T1 
fitting results at both time points, respectively. Decreased T1 values in the tumor region could clearly be 
observed 30 h after the injection of Gd(III)-DOTA-AaLS-R108C both with T1 maps and corresponding 
raw T1 fitting results.
MIP images of tumor bearing mice taken at sequential time points (pre, post, 2 h, 7 h, 12 h, and 
30 h) after the injection of Gd(III)-DOTA-AaLS-R108C were plotted in the first column of Fig.  3A. 
Immediately after the injection, blood vessels were brightened as the T1 values in the vessels signifi-
cantly decreased due to the contrast agent injection. As time progressed, positive contrast in blood vessel 
diminished and ~7 h after the injection, the positive contrast in the tumor region started to appear. T1 
shortening of tumor regions was further confirmed by T1 maps shown in the second column of Fig. 3B 
and the median-shift of the T1 histogram distribution of the whole 3D tumor volume, shown in the 
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Figure 2. Measurements of T1 and T2 relaxation times of Gd(III)-DOTA-AaLS-R108C at 1.4 T (A-1,A-2) 
and 7 T (C-1,C-2) . The inverse values of the T1 and T2 relaxation times (R1 and R2) are plotted against Gd(III) 
concentration, whose slopes determine corresponding relaxivities (r1 and r2) for 1.4 T (A-3) and 7 T (C-3). 
Corresponding relaxation times and relaxivities were measured for untreated AaLS solutions and shown for  
1.4 T (B-1–B-3) and 7 T (D-1–D-3).
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third column of Fig.  3C. Identical analysis was performed with conventional DOTAREM as shown in 
Fig. 3D–F. Blood vessels were also brightened right after the injection and dimming. Positive T1 contrast 
in the tumor region was apparent up to 2 h after the injection of DOTAREM, and positive T1 contrast 
diminished and the T1 values were restored to original values 7 h post-injection. Longitudinal maximum 
intensity projection (MIP) images before and after the injections of Gd(III)-DOTA-AaLS-R108C (n = 4) 
and DOTAREM (n = 2) were shown in supporting Figure S3.
Figure  4A,B present ROI analysis, showing the temporal trend of signal enhancement measured 
in the arterial region after injection with Gd(III)-DOTA-AaLS-R108C and conventional DOTAREM. 
The signal enhancement trend in artery caused by both agents had a similar pattern. Directly after 
injection, maximal arterial signal enhancements were obtained from both contrast agents, this enhance-
ment diminished as time progressed. A slower decreasing slope of arterial signal enhancement with 
Gd(III)-DOTA-AaLS-R108C than that from conventional DOTAREM was observed presumably from 
the elongated intravascular residence time of Gd(III)-DOTA-AaLS-R108C due to its size and hydrophilic 
surface. No meaningful arterial signal enhancements were observed 7 h and 30 h after injection with 
DOTAREM and Gd(III)-DOTA-AaLS-R108C, respectively.
Temporal variations of T1 values in both tumor and muscle on the other side of flank after 
injection with Gd(III)-DOTA-AaLS-R108C and DOTAREM were presented in Fig.  4C,D. For 
Gd(III)-DOTA-AaLS-R108C, the T1 value in the tumor slowly decreased in the first 2 h post-injection, 
and started to show a statistically significant change from 7 h post-injection (p < 0.05), while T1 in muscle 
showed no significant change at any time point. For DOTAREM on the other hand, the T1 value in the 
tumor reached the minimum value at the initial time point right after the injection, and then rapidly 
rebounded and returned to its original level at 7 h. T1 in muscle showed a similar trend to T1 in tumor, 
with relatively reduced changes of T1 values at each time point.
Figure 3. Representative (A) 3D MIP images, (B) T1-maps, and (C) Histogram of T1 values at various time 
points after injection of Gd(III)-DOTA-AaLS-R108C. Representative (D) 3D MIP images, (E) T1-maps, and 
(F) Histogram of T1 values at various time points after injection of conventional Gd-DOTA.
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Conclusions and Discussions
The high T1 relaxivity of Gd(III)-DOTA-AaLS-R108C may result from the slow tumbling rate of its large 
cage architecture28. Most previous studies performed with VLPs and protein complexes as supramolec-
ular conjugates haven shown relaxivities of 10–50 mM−1s−1, depending on experimental conditions23–27. 
When compared with experiments of Gd(III)-DOTA chelating agent conjugates we have performed 
previously, our measured value at 1.4 T (30.24 mM−1s−1) was slightly lower than that of large VLPs, 
P22 K118C WB (35.8 mM−1s−1), but slightly higher than small sized ferritin (19.9 mM−1s−1)23. The T1 
enhancement ability (r1/r2) tends to decrease significantly as the magnetic field is increased and often 
represents a major problem when applying macromolecular contrast agents at high field. The meas-
ured r1/r2 ratio (0.52) of Gd(III)-DOTA-AaLS-R108C at high magnetic field makes it attractive as a T1 
contrast agent at 7 T. It appears that the molecular hindrance mechanism and resulting dynamics of 
Gd(III)-chelating agent complexes conjugated to lumazine synthase determine overall relaxation char-
acteristics, but the exact explanation is unresolved at this point. Future relaxation simulation may shed 
more light on these experimental observations.
In vivo MIP images after the injection of Gd(III)-DOTA-AaLS-R108C show clearly defined vasculature, 
as shown in Fig. 3A. Compared with Gd-DOTA, which exhibited fast leakage in a rodent model of vascu-
lature imaging, intravascular Gd(III)-DOTA-AaLS-R108C appears to provide robust MR angiography at 
7 T. The temporal trend of signal enhancement in the arterial region shows that optimal signal enhance-
ment of the vasculature is achieved within 2 h of intravenous injection of Gd(III)-DOTA-AaLS-R108C.
As the longitudinal relaxation rate (R1) in tumor is generally known to be proportional to Gd(III) 
concentration, the absolute T1 (1/R1) map of tumor and muscle regions on the other hind leg ena-
bles the monitoring of temporal variations in Gd(III) accumulation of both regions, with minimized 
animal repositioning and slice mismatch errors occurring in longitudinal follow up studies. In other 
words, decreasing absolute T1 values in tissue should reflect increasing Gd(III) concentration of corre-
sponding region. The T1 value of the tumor decreased after the injected Gd(III)-DOTA-AaLS-R108C 
gradually migrated to the tumor region. A statistically significant decline in T1 value was observed 7 h 
post-injection, which coincides with a significant drop in signal enhancement in the arterial region. 
Figure 4. Temporal signal enhancement in arterial region after injection of (A) Gd(III)-DOTA-AaLS-R108C 
and (B) Gd-DOTA. (C,D) Temporal variation of median T1 values in tumor and muscle regions after the 
injection of Gd(III)-DOTA-AaLS-R108C and Gd-DOTA, respectively. (* represents statistical significance 
with p < 0.05).
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Compared to the short retention time (< 2 h) of DOTAREM, due to its relatively small size and low 
molecular weight45, Gd(III)-DOTA-AaLS-R108C showed a prolonged retention time in tumor. A consist-
ent T1 value in the other hind leg muscle away from the tumor supported the tumor-specific migration of 
Gd(III)-DOTA-AaLS-R108C, presumably due to the enhanced permeability and retention effects of the 
tumor46,50. These observations could be considered as the results of the abnormal characteristics of tumor 
tissue. In general, it is known that tumor tissues exhibit leaky vasculature and ineffective lymphatic drain-
age due to rapid and defective angiogenesis51. Hence, the tumor vasculature easily permits adequately 
sized macromolecules in plasma to escape from the tumor vessels and accumulate in tumor tissue for a 
specific time50,52. Meanwhile, although the long retention time of Gd(III)-DOTA-AaLS-R108C in tumor 
could be a strength in applications relating to anti-tumor therapy or drug delivery, it may raise toxicity 
concerns due to the release of free Gd(III) from prolonged retention, and further in vivo toxicity study 
should be followed.
This study demonstrates that newly developed Gd(III)-DOTA-AaLS-R108C could be successfully 
applied as a positive T1 MR contrast agent at high field, and utilized as a high-resolution vasculature 
imaging agent, active within 2 h of injection. Its prolonged retention time in tumors may be a key advan-
tage for a potential theranostic nanoplatform, as well as for future scientific investigations of optimized 
MRI T1 contrast agent at higher magnetic field.
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